Knight Therapeutics Inc.

Informe acción TSX:GUD

Capitalización de mercado: CA$579.8m

Salud financiera de hoja de balance de Knight Therapeutics

Salud financiera controles de criterios 5/6

Knight Therapeutics tiene un patrimonio de accionistas total de CA$746.9M y una deuda total de CA$61.9M, lo que sitúa su ratio deuda-patrimonio en 8.3%. Sus activos y pasivos totales son CA$945.5M y CA$198.6M respectivamente. El BAIT de Knight Therapeutics es de CA$6.4M, por lo que su ratio de cobertura de intereses es de -73.2. Tiene efectivo e inversiones a corto plazo que ascienden a CA$169.9M.

Información clave

8.3%

Ratio deuda-patrimonio

CA$61.87m

Deuda

Ratio de cobertura de intereses-73.2x
EfectivoCA$169.87m
PatrimonioCA$746.87m
Total pasivoCA$198.62m
Activos totalesCA$945.49m

Actualizaciones recientes sobre salud financiera

Recent updates

Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

May 28
Does Knight Therapeutics (TSE:GUD) Have A Healthy Balance Sheet?

Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

May 07
Shareholders May Not Be So Generous With Knight Therapeutics Inc.'s (TSE:GUD) CEO Compensation And Here's Why

Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Apr 07
Calculating The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

Mar 20
Read This Before Selling Knight Therapeutics Inc. (TSE:GUD) Shares

If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Mar 02
If You Had Bought Knight Therapeutics' (TSE:GUD) Shares Three Years Ago You Would Be Down 34%

Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Feb 03
Knight Therapeutics (TSE:GUD) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway

Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

Jan 19
Knight Therapeutics's (TSE:GUD) Earnings Are Growing But Is There More To The Story?

What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

Jan 04
What Type Of Shareholders Own The Most Number of Knight Therapeutics Inc. (TSE:GUD) Shares?

A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

Dec 20
A Look At The Fair Value Of Knight Therapeutics Inc. (TSE:GUD)

The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

Dec 07
The Founder of Knight Therapeutics Inc. (TSE:GUD), Jonathan Goodman, Just Bought A Few More Shares

What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Dec 02
What Type Of Returns Would Knight Therapeutics'(TSE:GUD) Shareholders Have Earned If They Purchased Their SharesYear Ago?

Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

Nov 17
Need To Know: The Consensus Just Cut Its Knight Therapeutics Inc. (TSE:GUD) Estimates For 2021

Análisis de la situación financiera

Pasivos a corto plazo: Los activos a corto plazo (CA$365.1M) de GUD superan a sus pasivos a corto plazo (CA$114.0M).

Pasivo a largo plazo: Los activos a corto plazo de GUD (CA$365.1M) superan a sus pasivos a largo plazo (CA$84.6M).


Historial y análisis de deuda-patrimonio

Nivel de deuda: GUD tiene más efectivo que su deuda total.

Reducción de la deuda: El ratio deuda-patrimonio de GUD ha crecido de 0% a 8.3% en los últimos 5 años.

Cobertura de la deuda: La deuda de GUD está bien cubierta por el flujo de caja operativo (58.1%).

Cobertura de intereses: GUD gana más intereses de los que paga, por lo que la cobertura de pagos de intereses no es preocupante.


Hoja de balance


Descubre empresas con salud financiera

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target

Price

7D

1Y

Mkt cap

PS

E.Growth

Analysts Target